Revolution Medicines booth at ASCO 2026
Pharma

FDA greenlights RevMed’s pancreatic cancer gamechanger

Following dynamite data that earned a standing ovation at ASCO, RevMed's star Ras inhibitor daraxonrasib has been approved by the FDA.
Darren Incorvaia Aug 26, 2026 11:30am
When is the new who The importance of timing in HCP marketing

When is the new who in HCP marketing

Brought to you by Phreesia Network Solutions
Magnifying glass with pills on blue

Regulatory tracker: GSK, ViiV Healthcare

Aug 26, 2026 2:40pm
Akeso

Akeso CEO touts biliary tract win, counters ivonescimab debate

Aug 26, 2026 11:11am
HHS headquarters as seen on April 02 2025

FDA weighs new drug, tech deputy commissioner posts: report

Aug 26, 2026 9:45am
Turkey flag Turkey magnifying glass Turkey investigation

Teva's patent and communications strategies in Turkey face probe

Aug 26, 2026 8:15am
More News

McKesson acquires Maryland CRO for $2.25 billion

Aug 25, 2026 11:22am

Jazz’s Ziihera nets FDA nod in first-line HER2+ stomach cancer

Aug 25, 2026 11:06am

Despite trial miss, Bausch + Lomb advances combo to ph. 3

Aug 25, 2026 10:46am
Fierce Biotech

Why a congressman says China is 'beating us on our ground game'

Aug 25, 2026 9:45am